Please assess the completion status of the following clinical trial:

Trial Title: A Two-Part 26-Week Study of Etoricoxib as Treatment for Ankylosing Spondylitis (AS) (MK-0663-108)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Has a definite diagnosis of Ankylosing Spondylitis (AS) per Modified New York Criteria made at least 6 months prior to screening~* Has a history of positive therapeutic benefit with non-steroidal anti-inflammatory drugs (NSAIDs) and regular use of NSAIDS for past 30 days~* Has a score on Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Question 2 at screening visit that is \<77 mm~* Must demonstrate sufficient flare or worsening of AS pain~* Is in general good health (other than AS)~* Has had approved non-study antirheumatic therapy that has been at stable dosing AND is not anticipated to undergo a change within the first 6 weeks of the protocol~Exclusion Criteria:~* Has inflammatory arthritis (eg, rheumatoid arthritis, psoriatic arthritis, crystal-induced arthritis, spondyloarthropathy, diffuse idiopathic skeletal hyperostosis \[DISH\]), polymyalgia rheumatica, a history of septic arthritis or intra-articular fracture of the study joint, Wilson's disease, hemachromatosis, ochronosis, or primary osteochondromatosis~* Has acute peripheral articular disease (onset within 4 weeks prior to screening) of an active (painful or swollen) peripheral arthritis~* Has a history of gastric or biliary surgery, or small intestine surgery that causes clinical malabsorption~* Has had an active peptic (gastric or duodenal) ulcer or history of inflammatory bowel disease~* Has undergone coronary artery bypass graft surgery (CABG), angioplasty, or has a cerebrovascular accident or transient ischemic attack within the past 6 months or has active ischemic heart disease, cerebrovascular disease, or peripheral vascular disease~* Has Class II-IV congestive heart failure~* Has uncontrolled hypertension~* Has a history of neoplastic disease, except adequately treated basal cell carcinoma or carcinoma in situ of the cervix, or malignancies that have been successfully treated ≥ 5 years prior to screening~* Has history of leukemia, lymphoma, malignant melanoma, and myeloproliferative disease~* Allergy to etoricoxib or naproxen, or history of a significant clinical or laboratory adverse experience associated with etoricoxib or naproxen~* Has a history or family history of an inherited or acquired bleeding disorder~* Is considered morbidly obese and demonstrates significant health problems stemming from obesity, which would confound study participation or interpretation of study results~* Is pregnant, breast-feeding, or expecting to conceive during the study~* Has a clinical diagnosis of hepatic insufficiency defined as Child-Pugh score ≥ 5

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- etoricoxib 60 mg/etoricoxib 60 mg (Type: EXPERIMENTAL): The etoricoxib 60 mg/etoricoxib 60 mg treatment sequence will receive etoricoxib 60 mg in Part I and Part II
- etoricoxib 60 mg/etoricoxib 90 mg (Type: EXPERIMENTAL): The etoricoxib 60 mg/etoricoxib 90 mg treatment sequence will receive etoricoxib 60 mg in Part I and etoricoxib 90 mg in Part II
- etoricoxib 90 mg/etoricoxib 90 mg (Type: EXPERIMENTAL): The etoricoxib 90 mg/etoricoxib 90 mg treatment sequence will receive etoricoxib 90 mg in Part I and Part II
- naproxen 1000 mg/naproxen 1000 mg (Type: ACTIVE_COMPARATOR): The naproxen 1000 mg/naproxen 1000 mg treatment sequence will receive naproxen 1000 mg in Part I and Part II

Based on this trial design, predict the completion outcome and termination type (if applicable).